Arrowpoint Investment Partners’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
VCM
VPM
Arrowpoint Investment Partners's BMY Position: Q1 2026 in Review
Arrowpoint Investment Partners sold out of Bristol-Myers Squibb (BMY) in Q1 2026, closing a stake of 10,806 shares — an estimated $583K sold.
Arrowpoint Investment Partners first reported a position in BMY in Q4 2025 and held it in 1 quarter. The position peaked at $583K in Q4 2025. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Arrowpoint Investment Partners reported no remaining Bristol-Myers Squibb position as of Q1 2026 after selling out during the quarter.
- Arrowpoint Investment Partners sold 10,806 Bristol-Myers Squibb shares in Q1 2026, an estimated $583K.
- Arrowpoint Investment Partners first reported a position in Bristol-Myers Squibb in Q4 2025 and held it in 1 quarter.
- Arrowpoint Investment Partners's Bristol-Myers Squibb position peaked at $583K in Q4 2025.
- 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Arrowpoint Investment Partners's 13F filing for Q1 2026, filed 14 May 2026.